pembrolizumab
merck
['pembro']
dr. cristina suarez discusses the updated results of kn564 with pfs do second line therapy analysis. adjuvant pembro delayed time to second disease progression with hr 0.57 #asco22 
Medical oncologist at @BPorgbr. Former fellow of GU oncology @DanaFarber @Harvard @MOCbrasil. #GUcancer